VA
MXCT icon

Valmark Advisers’s MaxCyte MXCT Stock Holding History

Valmark Advisers’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-123,203
Closed -$336K – 646
2025
Q1 		$336K Buy
123,203
+7,549
+7% +$29.8K 0.01% 492
2024
Q4 		$481K Buy
115,654
+2,478
+2% +$9.37K 0.01% 425
2024
Q3 		$440K Sell
113,176
-342
-0.3% -$1.44K 0.01% 440
2024
Q2 		$445K Sell
113,518
-2,562
-2% -$11K 0.01% 414
2024
Q1 		$486K Buy
116,080
+32,153
+38% +$151K 0.01% 386
2023
Q4 		$394K Buy
+83,927
New +$327K 0.01% 389
2023
Q3 		– Sell
-163,056
Closed -$748K – 481
2023
Q2 		$748K Buy
163,056
+91,177
+127% +$419K 0.02% 267
2023
Q1 		$356K Buy
71,879
+30,202
+72% +$149K 0.01% 365
2022
Q4 		$228K Buy
41,677
+7,118
+21% +$43.6K 0.01% 408
2022
Q3 		$225K Buy
+34,559
New +$193K ﹤0.01% 383

Other funds holding MXCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Valmark Advisers's MXCT Position: Q2 2025 in Review

Valmark Advisers sold out of MaxCyte (MXCT) in Q2 2025, closing a stake of 123,203 shares — an estimated $336K sold.

Valmark Advisers first reported a position in MXCT in Q3 2022 and held it in 10 quarters. The position peaked at $748K in Q2 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q2 2025.

  • Valmark Advisers reported no remaining MaxCyte position as of Q2 2025 after selling out during the quarter.
  • Valmark Advisers sold 123,203 MaxCyte shares in Q2 2025, an estimated $336K.
  • Valmark Advisers first reported a position in MaxCyte in Q3 2022 and held it in 10 quarters.
  • Valmark Advisers's MaxCyte position peaked at $748K in Q2 2023.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q2 2025.

Based on Valmark Advisers's 13F filing for Q2 2025, filed 23 Jul 2025.